Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
BUENA, N.J., April 26, 2018 -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30pm ET on Monday, May 7, 2018 to discuss the 1st quarter 2018 financial results and business update.
The Company invites you to listen to the call by dialing (866) 393-8366. International participants should call (409) 350-3154. Participants should ask to join the Teligent, Inc. call.
This call is available via webcast and can be accessed in the Investor Relations Section of Teligent, Inc.'s website at www.teligent.com.
About Teligent, Inc.
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.
Contact:
Damian Finio
Teligent, Inc.
(856) 336-9117
www.teligent.com
